Icagen and Pfizer have initiated Phase I trials for a candidate compound,Nav 1.7.A sodium channel-blocker,Nav 1.7 is believed to have promise for the treatment of pain and related disorders.The early trials will ascertain the safety,tolerability,pharmokinetics and optimal formulation of Nav 1.7.
Pfizer is funding all aspects of the collaboration.The pharma titan has exclusive worldwide rights to commercialize any products resulting from the partnership.For its part,Icagen may receive milestones and tiered royalties based upon product sales.
Icagen,located in Research Triangle Park,North Carolina,has identified multiple drug candidates that modulate ion channels.Ions are charged particles such as sodium,potassium and calcium.Ion channels are protein structures that span cell membranes and regulate the flow of ions into and out of cells.
Icagen is focused on oral medications for epilepsy,pain and inflammation that work by modulating these ion channels.
Icagen(ICGN),Pfizer(PFE)
Showing posts with label painkillers. Show all posts
Showing posts with label painkillers. Show all posts
Thursday, January 27, 2011
Thursday, October 14, 2010
Pfizer Loads Its Shopping Cart
Pharma titan Pfizer's purchase of King Pharmaceuticals,which was announced October 12,will augment its existing product lines in Primary Care,Established Products and Animal Health.The 3.6 billion dollar cash transaction brings new formulations of pain treatments that discourage misuse and abuse;the EpiPen auto-injection device;and a number of animal feed additives,into Pfizer's diversified businesses.
Pfizer CEO Jeff Kindler said they are highly impressed by King's innovative products and technology in the pain relief area.U.S. physicians wrote about 320 million prescriptions for painkillers in 2009.
Pfizer will also acquire King's promising new compounds in various stages of development.Pfizer already markets its own Celebrex and Lyrica painkilllers,and King will add Avinza,the Flector Patch and Embeda to the painkiller portfolio.
The deal is expected to close in late 2010 or early 2011,pending regulatory approval.
At the end of 2011,Pfizer's blockbuster drug Lipitor will go off-patent,resulting in a big loss of revenue.Pfizer is shopping for new income streams to help offset the loss of most of the billions Lipitor earns annually.In September,Pfizer announced its purchase of FoldRx Pharmaceuticals,a biotech firm specializing in neurodegenerative diseases.Last year,Pfizer bought Wyeth Pharmaceuticals for 68 billion dollars.
Pfizer(PFE)
Pfizer CEO Jeff Kindler said they are highly impressed by King's innovative products and technology in the pain relief area.U.S. physicians wrote about 320 million prescriptions for painkillers in 2009.
Pfizer will also acquire King's promising new compounds in various stages of development.Pfizer already markets its own Celebrex and Lyrica painkilllers,and King will add Avinza,the Flector Patch and Embeda to the painkiller portfolio.
The deal is expected to close in late 2010 or early 2011,pending regulatory approval.
At the end of 2011,Pfizer's blockbuster drug Lipitor will go off-patent,resulting in a big loss of revenue.Pfizer is shopping for new income streams to help offset the loss of most of the billions Lipitor earns annually.In September,Pfizer announced its purchase of FoldRx Pharmaceuticals,a biotech firm specializing in neurodegenerative diseases.Last year,Pfizer bought Wyeth Pharmaceuticals for 68 billion dollars.
Pfizer(PFE)
Subscribe to:
Posts (Atom)